Everstone Capital invests Rs 220 crore in Rubicon Research - Feedback

Everstone Capital has invested Rs 220 crore in contract research and drug delivery company Rubicon Research, the latest investment by the mid-market private equity firm, as it steps up its deal making pace, and continues to diversify its portfolio.

The $33 million investment, which has both, primary and secondary components, will also provide Kotak Private Equity, an early investor in Mumbai-based Rubicon Research, a full exit from the company, having invested Rs 60 crore till date. Post this transaction, Everstone will own a 70% stake in Rubicon. “Rubicon has an excellent record of providing cutting-edge solutions to the healthcare and pharmaceutical industry. We are excited about enhancing its capabilities,” said Sameer Sain, managing partner of the Everstone Group.


About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *